|
PA8474101A1
(es)
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
Compuestos de pirrolo [2,3-d] pirimidina
|
|
EP1065207A1
(en)
*
|
1999-07-02 |
2001-01-03 |
Aventis Pharma Deutschland GmbH |
Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
|
|
DE19948417A1
(de)
*
|
1999-10-07 |
2001-04-19 |
Morphochem Ag |
Imidazol-Derivate und ihre Verwendung als Arzneimittel
|
|
ES2306671T3
(es)
*
|
1999-10-07 |
2008-11-16 |
Amgen Inc. |
Inhibidores de triazina quinasa.
|
|
NZ518884A
(en)
|
1999-12-10 |
2004-02-27 |
Pfizer Prod Inc |
Pyrrolo[2,3-d]pyrimidine compounds
|
|
EP1782800B1
(en)
*
|
2000-01-24 |
2013-12-18 |
Genzyme Corporation |
Methods for detecting JAK3 inhibitors
|
|
CA2397774A1
(en)
*
|
2000-01-24 |
2001-07-26 |
Genzyme Corporation |
Jak/stat pathway inhibitors and the uses thereof
|
|
MY145722A
(en)
*
|
2000-04-27 |
2012-03-30 |
Abbott Lab |
Diazabicyclic central nervous system active agents
|
|
PL359563A1
(en)
|
2000-06-26 |
2004-08-23 |
Pfizer Products Inc. |
Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents
|
|
US6881737B2
(en)
|
2001-04-11 |
2005-04-19 |
Amgen Inc. |
Substituted triazinyl acrylamide derivatives and methods of use
|
|
US6864255B2
(en)
|
2001-04-11 |
2005-03-08 |
Amgen Inc. |
Substituted triazinyl amide derivatives and methods of use
|
|
US7301023B2
(en)
|
2001-05-31 |
2007-11-27 |
Pfizer Inc. |
Chiral salt resolution
|
|
GB0115393D0
(en)
*
|
2001-06-23 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
|
KR100875380B1
(ko)
*
|
2001-06-23 |
2008-12-23 |
아벤티스 파마슈티칼스 인크. |
단백질 키나제 억제제로서의 피롤로피리미딘
|
|
GB0119249D0
(en)
|
2001-08-07 |
2001-10-03 |
Novartis Ag |
Organic compounds
|
|
US7323469B2
(en)
|
2001-08-07 |
2008-01-29 |
Novartis Ag |
7H-pyrrolo[2,3-d]pyrimidine derivatives
|
|
GT200200234A
(es)
|
2001-12-06 |
2003-06-27 |
|
Compuestos cristalinos novedosos
|
|
US6642381B2
(en)
*
|
2001-12-27 |
2003-11-04 |
Hoffman-La Roche Inc. |
Pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds as protein tyrosine phosphatase inhibitors
|
|
DE60305446T4
(de)
|
2002-01-07 |
2009-07-09 |
Eisai R&D Management Co., Ltd. |
Desazapurine und deren verwendung
|
|
GB0202679D0
(en)
*
|
2002-02-05 |
2002-03-20 |
Glaxo Group Ltd |
Novel compounds
|
|
EP1388541A1
(en)
*
|
2002-08-09 |
2004-02-11 |
Centre National De La Recherche Scientifique (Cnrs) |
Pyrrolopyrazines as kinase inhibitors
|
|
EP1572213A1
(en)
|
2002-11-26 |
2005-09-14 |
Pfizer Products Inc. |
Method of treatment of transplant rejection
|
|
WO2004093812A2
(en)
*
|
2003-04-22 |
2004-11-04 |
Irm Llc |
Compounds that induce neuronal differentiation in embryonic stem cells
|
|
CA2543116A1
(en)
*
|
2003-10-27 |
2005-05-19 |
Genelabs Technologies, Inc. |
Methods for preparing 7-(2'-substituted-.szlig.-d-ribofuranosyl)-4-(nr2r3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
|
|
US20050153989A1
(en)
*
|
2004-01-13 |
2005-07-14 |
Ambit Biosciences Corporation |
Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
|
|
GB0403606D0
(en)
|
2004-02-18 |
2004-03-24 |
Novartis Ag |
Organic compounds
|
|
WO2005117909A2
(en)
*
|
2004-04-23 |
2005-12-15 |
Exelixis, Inc. |
Kinase modulators and methods of use
|
|
CA2571710A1
(en)
|
2004-06-24 |
2006-11-02 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
|
CA2572314A1
(en)
|
2004-06-29 |
2006-01-12 |
Christopher N. Farthing |
Pyrrolo[2,3-d]pyrimidines that modulate ack1 and lck activity
|
|
TW200615268A
(en)
|
2004-08-02 |
2006-05-16 |
Osi Pharm Inc |
Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
|
|
MY179032A
(en)
|
2004-10-25 |
2020-10-26 |
Cancer Research Tech Ltd |
Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
|
|
UY29177A1
(es)
|
2004-10-25 |
2006-05-31 |
Astex Therapeutics Ltd |
Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
|
|
AR054416A1
(es)
|
2004-12-22 |
2007-06-27 |
Incyte Corp |
Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
|
|
FR2880626B1
(fr)
*
|
2005-01-13 |
2008-04-18 |
Aventis Pharma Sa |
Derives de la purine, compositions les contenant et utilisation
|
|
WO2006091450A1
(en)
*
|
2005-02-18 |
2006-08-31 |
Lexicon Genetics Incorporated |
4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
|
|
CN101175753B
(zh)
|
2005-05-13 |
2011-03-23 |
Irm责任有限公司 |
作为蛋白激酶抑制剂的化合物和组合物
|
|
JP5071374B2
(ja)
|
2005-07-14 |
2012-11-14 |
アステラス製薬株式会社 |
ヘテロ環ヤヌスキナーゼ３阻害剤
|
|
CN102127078A
(zh)
|
2005-07-14 |
2011-07-20 |
安斯泰来制药株式会社 |
Janus激酶3的杂环类抑制剂
|
|
EP1926735A1
(en)
|
2005-09-22 |
2008-06-04 |
Incyte Corporation |
Tetracyclic inhibitors of janus kinases
|
|
EP1931674B1
(en)
*
|
2005-09-30 |
2012-12-12 |
Vertex Pharmaceuticals Incorporated |
Deazapurines useful as inhibitors of janus kinases
|
|
PL2455382T3
(pl)
*
|
2005-12-13 |
2017-04-28 |
Incyte Holdings Corporation |
Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej
|
|
AU2015201850B2
(en)
*
|
2005-12-13 |
2017-03-02 |
Incyte Holdings Corporation |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
|
|
BRPI0708779A2
(pt)
*
|
2006-03-11 |
2011-06-14 |
Vernalis R & D |
derivados de pirrolopirimidina utilizados como inibidores de hsp90
|
|
CN101460499A
(zh)
*
|
2006-04-05 |
2009-06-17 |
沃泰克斯药物股份有限公司 |
可用作janus激酶抑制剂的去氮杂嘌呤
|
|
GB0608176D0
(en)
*
|
2006-04-25 |
2006-06-07 |
Astex Therapeutics Ltd |
Pharmaceutical Compounds
|
|
ES2878130T3
(es)
*
|
2006-04-25 |
2021-11-18 |
Astex Therapeutics Ltd |
Derivados de purina y deazapurina como compuestos farmacéuticos
|
|
WO2008012635A2
(en)
*
|
2006-07-26 |
2008-01-31 |
Pfizer Products Inc. |
Amine derivatives useful as anticancer agents
|
|
US20080161320A1
(en)
*
|
2006-09-11 |
2008-07-03 |
Xiong Cai |
Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
|
|
JP2010502743A
(ja)
*
|
2006-09-11 |
2010-01-28 |
キュリス，インコーポレイテッド |
抗増殖薬剤としての多機能性低分子
|
|
AR064416A1
(es)
*
|
2006-12-21 |
2009-04-01 |
Cancer Rec Tech Ltd |
Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
|
|
WO2008075007A1
(en)
*
|
2006-12-21 |
2008-06-26 |
Cancer Research Technology Limited |
Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
|
|
US8513270B2
(en)
|
2006-12-22 |
2013-08-20 |
Incyte Corporation |
Substituted heterocycles as Janus kinase inhibitors
|
|
CA2675288A1
(en)
|
2007-01-12 |
2008-07-17 |
Astellas Pharma Inc. |
Condensed pyridine compound
|
|
JP2010523522A
(ja)
*
|
2007-04-02 |
2010-07-15 |
パラウ・フアルマ・ソシエダツド・アノニマ |
Ｊａｋ３阻害剤としてのピロロピリミジン誘導体
|
|
UA99284C2
(ru)
|
2007-05-11 |
2012-08-10 |
Елі Ліллі Енд Компані |
ИНГИБИТОРЫ р70 S6-КИНАЗЫ
|
|
EP3495369B1
(en)
|
2007-06-13 |
2021-10-27 |
Incyte Holdings Corporation |
Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
|
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
|
GB0713602D0
(en)
*
|
2007-07-12 |
2007-08-22 |
Syngenta Participations Ag |
Chemical compounds
|
|
WO2009016132A1
(en)
*
|
2007-07-27 |
2009-02-05 |
Janssen Pharmaceutica Nv |
Pyrrolopyrimidines
|
|
US8507672B2
(en)
*
|
2007-08-08 |
2013-08-13 |
Lexicon Pharmaceuticals, Inc. |
Substituted pyrrolo[2,3-d]pyrimidines as LIM kinase 2 inhibitors
|
|
WO2009030871A1
(en)
*
|
2007-09-07 |
2009-03-12 |
Vernalis R & D Ltd |
Pyrrolopyrimidine derivatives having hsp90 inhibitory activity
|
|
ES2522365T3
(es)
|
2007-10-11 |
2014-11-14 |
Astrazeneca Ab |
Derivados de pirrolo [2,3-D] pirimidina como inhibidores de proteína quinasas B
|
|
NZ585139A
(en)
|
2007-11-16 |
2012-05-25 |
Incyte Corp |
4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as jak inhibitors
|
|
ES2602577T3
(es)
|
2008-03-11 |
2017-02-21 |
Incyte Holdings Corporation |
Derivados de azetidina y ciclobutano como inhibidores de JAK
|
|
EP2674433A1
(en)
*
|
2008-04-21 |
2013-12-18 |
Lexicon Pharmaceuticals, Inc. |
LIMK2 inhibitors, compositions comprising them and methods of their use
|
|
US8871753B2
(en)
|
2008-04-24 |
2014-10-28 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
|
ME01269B
(me)
|
2008-08-20 |
2013-06-20 |
Zoetis Services Llc |
Jedinjenja pirolo (2,3-d) pirimidina
|
|
US8385364B2
(en)
*
|
2008-09-24 |
2013-02-26 |
Nec Laboratories America, Inc. |
Distributed message-passing based resource allocation in wireless systems
|
|
CL2009001884A1
(es)
*
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
|
JOP20190231A1
(ar)
|
2009-01-15 |
2017-06-16 |
Incyte Corp |
طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
|
|
DE102009005193A1
(de)
*
|
2009-01-20 |
2010-07-22 |
Merck Patent Gmbh |
Neue heterocyclische Verbindungen als MetAP-2 Inhibitoren
|
|
WO2010085597A1
(en)
|
2009-01-23 |
2010-07-29 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
|
CA2752150A1
(en)
|
2009-02-11 |
2010-08-19 |
Reaction Biology Corp. |
Selective kinase inhibitors
|
|
CA3025627C
(en)
|
2009-04-20 |
2021-08-31 |
Auspex Pharmaceuticals, Inc. |
Piperidine inhibitors of janus kinase 3
|
|
NZ596479A
(en)
*
|
2009-05-22 |
2014-01-31 |
Incyte Corp |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
TWI484962B
(zh)
|
2009-05-22 |
2015-05-21 |
Incyte Corp |
作為ｊａｋ抑制劑之３－〔４－（７ｈ－吡咯并〔２，３－ｄ〕嘧啶－４－基）－１ｈ－吡唑－１－基〕辛烷或庚腈
|
|
US9346809B2
(en)
|
2009-07-08 |
2016-05-24 |
Leo Pharma A/S |
Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors
|
|
TWI466885B
(zh)
|
2009-07-31 |
2015-01-01 |
Japan Tobacco Inc |
含氮螺環化合物及其醫藥用途
|
|
TW201111385A
(en)
*
|
2009-08-27 |
2011-04-01 |
Biocryst Pharm Inc |
Heterocyclic compounds as janus kinase inhibitors
|
|
WO2011028685A1
(en)
|
2009-09-01 |
2011-03-10 |
Incyte Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
CN107011330B
(zh)
|
2009-09-04 |
2020-07-03 |
比奥根Ma公司 |
布鲁顿酪氨酸激酶抑制剂
|
|
EP2473054B1
(en)
*
|
2009-09-04 |
2017-06-14 |
The Regents of the University of Michigan |
Compositions and methods for treatment of leukemia
|
|
CN105541847B
(zh)
|
2009-10-09 |
2019-08-16 |
因西特控股公司 |
3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物
|
|
CN102574860A
(zh)
|
2009-10-15 |
2012-07-11 |
辉瑞大药厂 |
吡咯并[2,3-d]嘧啶化合物
|
|
US9074143B2
(en)
*
|
2009-12-11 |
2015-07-07 |
Uop Llc |
Process for producing hydrocarbon fuel
|
|
CA2782720A1
(en)
|
2009-12-18 |
2011-06-23 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidine compounds
|
|
JP2013518882A
(ja)
|
2010-02-05 |
2013-05-23 |
ファイザー・インク |
ＪＡＫ阻害剤としてのピロロ［２，３−ｄ］ピリミジン尿素化合物
|
|
JP5858434B2
(ja)
*
|
2010-02-18 |
2016-02-10 |
インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｊａｎｕｓキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体
|
|
HUE028723T2
(en)
|
2010-03-10 |
2016-12-28 |
Incyte Holdings Corp |
Piperidin-4-yl azetidine derivatives as JAK-1 inhibitors
|
|
KR102402137B1
(ko)
|
2010-05-21 |
2022-05-30 |
인사이트 홀딩스 코포레이션 |
Ｊａｋ 저해제에 대한 국소 제형
|
|
CN102985425A
(zh)
*
|
2010-07-09 |
2013-03-20 |
利奥制药有限公司 |
作为蛋白酪氨酸激酶抑制剂的新的高哌嗪衍生物及其医药用途
|
|
WO2012022045A1
(en)
*
|
2010-08-20 |
2012-02-23 |
Hutchison Medipharma Limited |
Pyrrolopyrimidine compounds and uses thereof
|
|
CN102372717B
(zh)
*
|
2010-08-20 |
2014-06-18 |
和记黄埔医药（上海）有限公司 |
吡咯并嘧啶类化合物及其用途
|
|
BR112013003864B1
(pt)
|
2010-08-20 |
2021-08-31 |
Hutchison Medipharma Limited |
Compostos de pirrolpirimidina, composição e uso dos mesmos
|
|
TWI401258B
(zh)
*
|
2010-09-08 |
2013-07-11 |
Hutchison Medipharma Ltd |
吡咯並嘧啶類化合物及其用途
|
|
CA2818545C
(en)
|
2010-11-19 |
2019-04-16 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
|
|
AU2011329734B2
(en)
|
2010-11-19 |
2015-05-28 |
Incyte Holdings Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
|
EP2651417B1
(en)
|
2010-12-16 |
2016-11-30 |
Calchan Limited |
Ask1 inhibiting pyrrolopyrimidine derivatives
|
|
WO2012088682A1
(en)
*
|
2010-12-29 |
2012-07-05 |
Shanghai Fochon Pharmaceutical Co Ltd. |
2-(3-aminopiperidin-1-yl)-[1,2,4]triazolo[1,5-c]pyrimidine-5,7(3h,6h)-dione derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
|
|
MX2013007792A
(es)
*
|
2011-01-07 |
2013-07-30 |
Leo Pharma As |
Nuevos derivados de sulfamida piperazina como inhibidores de proteina tirosina cinasa y uso farmaceutico de los mismos.
|
|
DE102011008352A1
(de)
*
|
2011-01-12 |
2012-07-12 |
Merck Patent Gmbh |
5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
|
|
WO2012106522A2
(en)
|
2011-02-04 |
2012-08-09 |
Duquesne University Of The Holy Spirit |
Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
|
|
KR102024948B1
(ko)
|
2011-02-18 |
2019-11-04 |
노파르티스 파르마 아게 |
mTOR/JAK 저해제 병용 요법
|
|
AU2012232658B2
(en)
|
2011-03-22 |
2016-06-09 |
Advinus Therapeutics Limited |
Substituted fused tricyclic compounds, compositions and medicinal applications thereof
|
|
SI2694056T1
(sl)
|
2011-04-01 |
2019-12-31 |
Astrazeneca Ab |
Terapevtsko zdravljenje
|
|
AR086983A1
(es)
|
2011-06-20 |
2014-02-05 |
Incyte Corp |
Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
|
|
TWI574965B
(zh)
*
|
2011-06-29 |
2017-03-21 |
默沙東藥廠 |
二肽基肽酶－ｉｖ抑制劑之新穎結晶型
|
|
EA201490229A1
(ru)
|
2011-07-08 |
2014-05-30 |
Новартис Аг |
Новые пирролопиримидиновые производные
|
|
HK1198579A1
(en)
|
2011-08-10 |
2015-04-30 |
Novartis Pharma Ag |
Jak p13k/mtor combination therapy
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
ES3018133T3
(en)
|
2011-11-30 |
2025-05-14 |
Univ Emory |
Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
|
|
MX367640B
(es)
|
2011-11-30 |
2019-08-29 |
Astrazeneca Ab |
Tratamiento combinado del cáncer.
|
|
WO2013085802A1
(en)
*
|
2011-12-06 |
2013-06-13 |
Merck Sharp & Dohme Corp. |
Pyrrolopyrimidines as janus kinase inhibitors
|
|
AU2013204533B2
(en)
|
2012-04-17 |
2017-02-02 |
Astrazeneca Ab |
Crystalline forms
|
|
AR091079A1
(es)
|
2012-05-18 |
2014-12-30 |
Incyte Corp |
Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
|
|
AR091273A1
(es)
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
Inhibidores de pirimidinil tirosina quinasa
|
|
JP6189948B2
(ja)
|
2012-06-29 |
2017-08-30 |
ファイザー・インク |
ＬＲＲＫ２阻害薬としての新規な４−（置換アミノ）−７Ｈ−ピロロ［２，３−ｄ］ピリミジン
|
|
US10227357B2
(en)
|
2012-09-06 |
2019-03-12 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
US9593115B2
(en)
|
2012-09-21 |
2017-03-14 |
Advinus Therapeutics Ltd. |
Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
|
|
CN104662024B
(zh)
*
|
2012-10-26 |
2016-12-07 |
弗·哈夫曼-拉罗切有限公司 |
酪氨酸激酶抑制剂
|
|
CN102936251A
(zh)
*
|
2012-11-05 |
2013-02-20 |
上海毕得医药科技有限公司 |
一种吡咯并[2,3-d]嘧啶衍生物的制备方法
|
|
EA201590930A1
(ru)
|
2012-11-15 |
2015-08-31 |
Инсайт Корпорейшн |
Лекарственные формы руксолитиниба с замедленным высвобождением
|
|
PL2958921T3
(pl)
|
2013-02-22 |
2018-01-31 |
Pfizer |
Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinaz janusowych (jak)
|
|
UA120162C2
(uk)
|
2013-03-06 |
2019-10-25 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки при отриманні інгібітора jak
|
|
US9650375B2
(en)
|
2013-03-14 |
2017-05-16 |
Merck Sharp & Dohme Corp. |
Indole derivatives useful as anti-diabetic agents
|
|
PH12019502074B1
(en)
|
2013-08-07 |
2023-10-18 |
Incyte Holdings Corp |
Sustained release dosage forms for a jak1 inhibitor
|
|
AU2014358792C1
(en)
|
2013-12-05 |
2021-08-26 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
|
|
ES2663622T3
(es)
|
2013-12-17 |
2018-04-16 |
Pfizer Inc. |
Novedosas 1H-pirrolo[2,3-b]piridinas 3,4-disustituidas y 7H-pirrolo[2,3-c]piridacinas 4,5-disustituidas como inhibidores de LRRK2
|
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
|
WO2016024185A1
(en)
|
2014-08-12 |
2016-02-18 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
|
|
USRE49687E1
(en)
|
2014-09-09 |
2023-10-10 |
The Regents Of The University Of Michigan |
Thienopyrimidine and thienopyridine compounds and methods of use thereof
|
|
CN105524067A
(zh)
*
|
2014-09-28 |
2016-04-27 |
江苏柯菲平医药股份有限公司 |
4-取代吡咯并[2,3-d]嘧啶化合物及其用途
|
|
JP6761815B2
(ja)
|
2015-05-01 |
2020-09-30 |
ファイザー・インク |
ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、ピロロ［２，３−ｂ］ピリジニルアクリルアミド、およびそのエポキシド
|
|
AR104020A1
(es)
|
2015-06-04 |
2017-06-21 |
Kura Oncology Inc |
Métodos y composiciones para inhibir la interacción de menina con proteínas mill
|
|
US10588907B2
(en)
|
2015-06-04 |
2020-03-17 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with MLL proteins
|
|
RU2712269C2
(ru)
*
|
2015-07-31 |
2020-01-28 |
Тайхо Фармасьютикал Ко., Лтд. |
Пирроло[2,3-d]пиримидиновое соединение или его соль
|
|
KR101771219B1
(ko)
*
|
2015-08-21 |
2017-09-05 |
양지화학 주식회사 |
야누스 키나제 1 선택적 억제제 및 그 의약 용도
|
|
WO2017046675A1
(en)
|
2015-09-14 |
2017-03-23 |
Pfizer Inc. |
Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
|
|
CN108472298B
(zh)
|
2015-11-24 |
2021-04-20 |
深圳阿拉丁医疗科技有限公司 |
选择性激酶抑制剂
|
|
CN107098908B
(zh)
*
|
2016-02-23 |
2021-01-08 |
欣凯医药科技(上海)有限公司 |
一种吡咯并嘧啶类化合物的制备方法和应用
|
|
LT3429591T
(lt)
|
2016-03-16 |
2023-07-10 |
Kura Oncology, Inc. |
Pakeistojo tieno[2,3-d]pirimidino dariniai kaip menino-mll inhibitoriai ir jų panaudojimo būdai
|
|
CN109640987B
(zh)
|
2016-03-16 |
2022-12-02 |
库拉肿瘤学公司 |
Menin-mll的桥联双环抑制剂及使用方法
|
|
CN107513069A
(zh)
*
|
2016-06-16 |
2017-12-26 |
正大天晴药业集团股份有限公司 |
手性吡咯并嘧啶化合物的制备方法
|
|
CN107513067A
(zh)
|
2016-06-16 |
2017-12-26 |
北京赛林泰医药技术有限公司 |
含有取代环戊基的吡咯并嘧啶化合物
|
|
AU2017298035B2
(en)
|
2016-07-21 |
2021-10-28 |
Biogen Ma Inc. |
Succinate forms and compositions of Bruton's tyrosine kinase inhibitors
|
|
WO2018140648A1
(en)
|
2017-01-25 |
2018-08-02 |
Eric Jon Jacobsen |
Pyrrolopyrimidine itk inhibitors for treating inflammation and cancer
|
|
JP7101176B2
(ja)
*
|
2017-02-03 |
2022-07-14 |
レオ ファーマ アクティーゼルスカブ |
新規ＪＡＫキナーゼ阻害剤としての５－（７Ｈ－ピロロ［２，３－ｄ］ピリミジン－４－イル）－５－アザスピロ［２．５］オクタン－８－カルボン酸誘導体
|
|
JP7628392B2
(ja)
|
2017-03-24 |
2025-02-10 |
クラ オンコロジー，インク． |
血液悪性腫瘍およびユーイング肉腫を処置するための方法
|
|
CN108794480A
(zh)
*
|
2017-04-28 |
2018-11-13 |
天津药物研究院有限公司 |
吡咯并嘧啶类化合物、其制备方法和用途
|
|
WO2018226976A1
(en)
|
2017-06-08 |
2018-12-13 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with mll proteins
|
|
US11649251B2
(en)
|
2017-09-20 |
2023-05-16 |
Kura Oncology, Inc. |
Substituted inhibitors of menin-MLL and methods of use
|
|
JP2021502400A
(ja)
|
2017-11-03 |
2021-01-28 |
アクラリス セラピューティクス，インコーポレイテッド |
置換ピロロピリミジンｊａｋ阻害剤ならびにこれを作製および使用する方法
|
|
WO2019090143A1
(en)
|
2017-11-03 |
2019-05-09 |
Aclaris Therapeutics, Inc. |
Pyrazolyl pyrrolo[2,3-b]pyrimidine-5-carboxylate analogs and methods of making the same
|
|
TW201924683A
(zh)
|
2017-12-08 |
2019-07-01 |
美商英塞特公司 |
用於治療骨髓增生性贅瘤的低劑量組合療法
|
|
EA202091830A1
(ru)
|
2018-01-30 |
2020-12-29 |
Инсайт Корпорейшн |
Способы и промежуточные соединения для получения ингибитора jak
|
|
HRP20240741T1
(hr)
|
2018-03-30 |
2024-12-06 |
Incyte Corporation |
Liječenje hidradenitis suppurativa uporabom jak inhibitora
|
|
CA3109192A1
(en)
|
2018-08-10 |
2020-02-13 |
Aclaris Therapeutics, Inc. |
Pyrrolopyrimidine itk inhibitors
|
|
GB201818750D0
(en)
*
|
2018-11-16 |
2019-01-02 |
Institute Of Cancer Res Royal Cancer Hospital |
Lox inhibitors
|
|
CN109394768B
(zh)
*
|
2018-12-10 |
2019-08-23 |
牡丹江医学院 |
一种治疗湿疹的药物及其制备方法
|
|
NL2022471B1
(en)
|
2019-01-29 |
2020-08-18 |
Vationpharma B V |
Solid state forms of oclacitinib
|
|
WO2020198583A1
(en)
|
2019-03-27 |
2020-10-01 |
Insilico Medicine Ip Limited |
Bicyclic jak inhibitors and uses thereof
|
|
KR20220004726A
(ko)
|
2019-05-02 |
2022-01-11 |
어클라리스 쎄라퓨틱스, 인코포레이티드 |
Jak 억제제로서의 치환된 피롤로피리딘
|
|
KR102503349B1
(ko)
|
2019-05-14 |
2023-02-23 |
프로벤션 바이오, 인코포레이티드 |
제1형 당뇨병을 예방하기 위한 방법 및 조성물
|
|
EP4061367A1
(en)
|
2019-11-22 |
2022-09-28 |
Incyte Corporation |
Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
JP2023530109A
(ja)
|
2020-06-11 |
2023-07-13 |
プロヴェンション・バイオ・インコーポレイテッド |
１型糖尿病を予防するための方法および組成物
|
|
US20250051337A1
(en)
*
|
2021-09-28 |
2025-02-13 |
Sanford Burnham Prebys Medical Discovery Institute |
Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof
|